Phosphorylation of Varicella-Zoster Virus IE63 Protein by Casein Kinases Influences Its Cellular Localization and Gene Regulation Activity*

Received for publication, December 13, 2001, and in revised form, March 20, 2002
Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M111872200

Sébastien Bontems‡, Emmanuel Di Valentin§, Laurence Baudoux, Bernard Rentier, Catherine Sadzot-Delvaux, and Jacques Piette†

From the Laboratory of Virology and Immunology, University of Liège, B-4000 Liège, Belgium

During the early phase of varicella-zoster virus (VZV) infection, Immediate Early protein 63 (IE63) is expressed rapidly and abundantly in the nucleus, while during latency, this protein is confined mostly to the cytoplasm. Because phosphorylation is known to regulate many cellular events, we investigated the importance of this modification on the cellular localization of IE63 and on its regulatory properties. We demonstrate here that cellular casein kinases I and II are implicated in the in vitro and in vivo phosphorylation of IE63. A mutational approach also indicated that phosphorylation of the protein is important for its correct cellular localization in a cell type-dependent fashion. Using an activity test, we demonstrated that IE63 was able to repress the gene expression driven by two VZV promoters and that phosphorylation of the protein was required for its full repressive properties. Finally, we showed that IE63 was capable of exerting its repressive activity in the cytoplasm, as well as in the nucleus, suggesting a regulation at the transcriptional and/or post-transcriptional level.

The varicella-zoster virus (VZV) is a neurotropic virus belonging to the Alphaherpesvirinae subfamily and responsible for two distinct diseases as follows: chicken pox, an illness affecting mostly young children, and shingles, resulting from the virus reactivation in elderly and immunocompromised people (1). Indeed, the characteristics of all members of this viral subfamily are their ability to establish latency in sensory ganglia after primary infection and to reactivate decades later. Molecular events leading to the establishment and maintenance of the virus latency, as well as to its reactivation, are still poorly understood. It appears to be the result of a delicate balance between cellular factors, viral proteins and the host immune system (2). In lytically infected cells, the expression of VZV genes seems to occur in cascade-like events, previously described for herpes simplex virus type 1 (HSV-1) (3). Immediate early (IE) gene-encoded proteins are the first ones to be active because they act as regulators on their own expression, as well as on the transcriptional activation of early (E) and late (L) genes. Among the immediate early proteins, IE62 seems to be the major regulating factor with regard to its transcriptional properties on all classes of viral genes (4–8).

Transcripts from several VZV open reading frames (ORFs 4, 21, 29, 62, and 63) have been detected in latently infected human ganglia (9–15). Moreover, several of the corresponding proteins have been detected in latently infected cells (16–18). During latency, the expression of viral proteins also present during the lytic phase of infection is an original feature that VZV does not share with HSV-1. IE63 was the first protein described in a latency context, first in an animal model (19) and second in human tissue sections (16–18). This 45-kDa phosphoprotein, encoded by two identical ORFs (ORF63 and ORF70), is present in the virion tegument (19). IE63 is abundantly produced during the early phase of infection (20) and is essential for VZV replication (21). Its activity as a potential transcription factor remains unclear. IE63 has been shown to exert positive or negative effects on gene transcription, depending on the type of promoter studied (22). However, others claimed that IE63 played only a minor role in the control of VZV gene expression (23). An interesting feature of the VZV IE63 protein is its cellular localization during the different stages of the viral cycle. Indeed, in the early phase of infection, IE63 is predominantly present in the nucleus of infected cells (20). On the other hand, IE63 exhibits an exclusive cytoplasmic localization during latency and can be found both in the nucleus and the cytoplasm when reactivation occurs (17). The presence of IE63 and its localization modification might reflect an important role in the latency process. Phosphorylation and dephosphorylation events are known to be usually involved in regulation mechanisms such as nuclear and cytoplasmic translocation, for example. In vitro phosphorylation of IE63 may be achieved using recombinant casein kinase II (CKII), and the protein is also phosphorylated in VZV-transfected Mewo cells (24). The phosphorylation sites used in these in vivo and in vitro assays are located predominantly at the carboxyl-terminal region of the protein. Recently, it has also been shown that IE63 is a substrate for ORF47, one of the VZV-encoded kinases (25). Indeed, using stringent in vitro conditions, an extensive phosphorylation of the protein is catalyzed by the ORF47-encoded kinase, which can compete with CKII for the binding to IE63. This viral serine/threonine kinase has often been compared with CKII, notably because they may both use ATP or
GTP as phosphate donor (26). These results demonstrate that viral and cellular kinases are capable of phosphorylating IE63.

The purpose of this paper was to analyze in further detail the IE63 phosphorylation status. For this, we used a mutational approach to investigate the importance of some of the putative phosphorylation sites on the cellular localization of IE63 and on its activity. Ten potential phosphorylation sites for casein kinase I (CKI), CKII, and protein kinase C (PKC) or Cdc2 were mutated, and in vitro kinase assays were carried out using these mutated proteins as substrates. Results indicated that these sites are important in the phosphorylation process of IE63, using either recombinant CKI and CKII or protein extracts from Vero (non-neuronal) or ND7 (neuronal) cells. Immunofluorescent studies on these neuronal and non-neuronal cell lines transfected with the mutated IE63 proteins indicated that phosphorylation on these residues is required for a suitable cellular localization of the protein in Vero but not in ND7 cells. We also demonstrated that wild-type IE63 protein possesses some repressive properties on two VZV promoters (DNA polymerase and thymidine kinase) and that mutation of the phosphorylation sites strongly impaired its activity. Finally, we also witnessed evidence of an important feature of this protein: IE63 is able to exert its repressive activity both in the nucleus and in the cytoplasm of transfected cells, suggesting that IE63 acts through a transcriptional or post-transcriptional mechanism in the nucleus and/or through a post-transcriptional mechanism in the cytoplasm of transfected cells.

**Experimental Procedures**

**Plasmids**—The wild-type IE63 gene was amplified by PCR from the pGEX-63 (20) and cloned in the pcDNA3.1– vector (Invitrogen) to generate the pcDNA63 wt. We also constructed the pcDNA63 świne, where the hemagglutinin (HA) sequence was replaced by the influenza hemagglutinin (H1) sequence. This plasmid was used as negative control in some experiments. Mutations were introduced into the IE63 gene by PCR using the site-directed mutagenesis kit system (Stratagene). For this, several sets of primers were synthesized (Eurogentec). Table I summarizes the strategy used. All mutated genes were cloned in the pGEX-5x (Amersham Biosciences) and transformed in Escherichia coli JM109 strain in order to produce GST fusion proteins. All constructions were subsequently sequenced to verify that no additional mutations were introduced during PCR.

To generate pcDNA-63ΔK, the carboxyl-terminal region of IE63 (from amino acids 210 to 278) was removed by digestion of pcDNA63 wt with Kpnl and self-ligation. The putative nuclear localization signal (NLS), from amino acids 260 to 263, was removed by digesting pcDNA63 vector at ClaI sites (previously added by PCR) and self-ligation in order to generate pcDNA-63ΔNLS. A plasmid (pPol-luc), where the luciferase reporter gene was under the control of the VZV DNA polymerase gene promoter (pPol), was constructed by inserting a 404-bp-long fragment from the pPol gene by PCR from the pcDNA 3.1– (Amersham Biosciences) as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol. GST-IeBa protein was used as positive control and produced as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol. GST-IeBa protein was used as positive control and produced as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol. GST-IeBa protein was used as positive control and produced as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol.

For some in vitro kinase assays, protein extracts were dialyzed with a high volume (up to 2 liter) of casein kinase II buffer (50 mM Tris-HCl, pH 7.4, 140 mM KCl, and 10 mM MgCl2) for 2 h. Protein concentrations were measured by the Bradford method (Bio-Rad).

**Immunoprecipitations**—CKI and CKII were immunoprecipitated from Vero and ND7 cellular extracts using polyclonal antibodies raised against CKI (R-19: sc-6474, from Santa Cruz Biotechnology, Inc.) and CKII (C-18: sc-6479, from Santa Cruz Biotechnology, Inc.), respectively. 40 μl of protein A-Sepharose (Amersham Biosciences) were incubated overnight at 4 °C with 5 μl of antibodies and several concentrations of cellular extract (previously immunoprecipitated with mouse antibodies against VZV Tris-HCI, pH 7.5, 200 mM NaCl, 0.5% Nonidet P-40, Complete Protease Inhibitors, Roche Molecular Biochemicals) that included a mixture of phosphatase inhibitors (1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 0.5 mM β-glycerophosphate). The resin was then washed 3 times with cold CKII buffer.

**In Vitro Kinase Assays**—GST-63 wt protein was expressed from the plasmid pGEX-63ΔK on glutathione-Sepharose 4B (Amersham Biosciences) as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol. GST-IeBa protein was used as positive control and produced as described previously (20). Mutant GST-63 proteins were expressed and purified according to the same protocol. GST-IeBa protein was used as positive control and produced as described previously (29). In vitro kinase assays were performed with cellular extracts, recombinant kinases, or immunoprecipitated kinases. Several concentrations of cellular extracts or recombinant kinases were added to 20 μl of glutathione-Sepharose 4B-bound GST-63 protein and with 10 μCi of [γ-32P]ATP (ICN). For the assays using the immunoprecipitated kinases, 10 μl of [γ-32P]ATP (ICN) and 2 μg of GST-63 (eluted from the resin using 10 μl GSH in 50 mM Tris-HCl, pH 8) were added to resin-bound kinases. All reactions were performed in CKII buffer, supplemented with the protease and phosphatase inhibitors mixtures, for 30 min at 30 °C. Resins were washed 5 times with CKII buffer. The samples were loaded on a 10% SDS-PAGE gel. After migration, the gel was dried and autoradiographed on a Fuji x-ray film (General Electrics). Quantifications were carried out by PhosphoImaging (Molecular Dynamics).

For some in vitro kinase assays, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) (ICN), which is an inhibitor of casein kinases, was used at several concentrations.

**Transient Transfection Studies**—Transfection studies were carried out with cells (Vero or ND7) seeded into 35-mm diameter 6-well cluster dishes using the FuGENE 6 transfectant reagent according to the manufacturer’s prescriptions (Roche Molecular Biochemicals). In these experiments, pPol-luc or pTkCAT-L was used as reporter vectors and pcDNA 3.1–, pcDNA562, pcDNA3 wt, pcDNA63 5M, pcDNA63 10M, and
Identification and Mutation of the Putative Phosphorylation Sites in the Carboxyl-terminal Region of IE63—Previous studies suggested that important phosphorylation sites are located in the carboxyl-terminal region (amino-acids 142–278) of the IE63 protein (24). Therefore, we decided to focus our work on this part of the IE63 protein. A computer analysis was carried out to identify putative phosphorylation sites for cellular kinases in the carboxyl-terminal region of IE63. For this, we used the PhosphoBlast prediction tool software available on the Center for Biological Sequence Analysis web site (31). As shown in Fig. 1, the analysis revealed the presence of 10 potential phosphorylatable serine or threonine residues in this region. Five of them (Ser-150, Ser-165, Ser-181, Ser-186, and Thr-171) are important targets for CKII and four others (Ser-173, Ser-185, Thr-201, and Thr-244) for CKI. The Ser-224 was found to be a putative site for PKC and/or p34 

\[\text{PKC and/or p34} \] 

mediated phosphorylation. In order to assay the importance of these residues in IE63 phosphorylation, we decided to substitute them by alanine residues. The IE63 gene was cloned first in the pcDNA3.1—expression vector (Invitrogen) to generate wild-type pcDNA63. We then used a PCR-based mutagenesis strategy to generate mutants. Resulting plasmids are listed in Table I. For example, in pcDNA63-5M, only the five potential phosphorylation sites for CKII were mutated, whereas in pcDNA63-10M, all 10 potential sites for CKI, CKII, and PKC/Cdc2-mediated phosphorylation were mutated (Table I).

In Vitro Kinase Assays Using Recombinant CKI and CKII—The mutated IE63-encoding genes were cloned in pGEX-5x vector (Amersham Biosciences) to generate GST fusion proteins. The expression of the purified fusion proteins was verified by Coomassie Blue-stained SDS-PAGE gel (Fig. 2, A and B) and Western blotting analysis (data not shown). In order to improve the impact of the mutations on the phosphorylation rate of the protein, in vitro kinase assays were carried out using recombinant CKI and CKII on GST-IE63-Sepharose-bound proteins. Phosphorylation of wild-type IE63 was observed using increasing concentrations of both CKI and CKII (from 10–50 units) (Fig. 2, A and B). Mutation of the five putative phosphorylation sites for CKII (GST-IE63-5M) led to a slight decrease of the in vitro phosphorylation rate, while, surprisingly, the IE63 phosphorylation rate observed using CKI was somewhat increased. In vitro phosphorylation of the GST-IE63-10M protein, where 10 putative phosphorylation sites for CKI and CKII were mutated into alanine residues, showed an important decrease of the phosphorylation rate for both kinases. These results indicated that the residues aimed in our study are important for the in vitro IE63 phosphorylation by CKI and CKII. It also suggested that a few phosphorylation sites for both kinases might still be present elsewhere in the protein because the mutation of the 10 residues did not totally abolish the phosphorylation rate of IE63.

In Vitro Kinase Assays Using Cellular Extracts—To determine whether cellular kinases were able to phosphorylate the IE63 protein, we carried out kinase assays using cellular protein extracts. An in vitro kinase assay was then performed on wild-type GST-IE63 using 50 µg of total, cytoplasmic, or nuclear protein extracts from Vero cells previously dialyzed against CKII buffer (Fig. 3A). In this experiment GST-IxBe protein was used as a positive control because its CKII-mediated phosphorylation was described by several authors (30, 32). An intense phosphorylation of wild-type GST-IE63 using total, cytoplasmic, or nuclear protein extracts from Vero cells was observed. This phosphorylation was strongly reduced when reaction was performed in the presence of 2 mM DRB, an inhibitor of both CKI and CKII (33). This experiment allowed us to conclude that extracts from Vero cells contain casein kinase activities almost equally present in the nucleus and the cytoplasm. In order to confirm the presence and the activity of these kinases in cellular extracts, CKI and CKII were immunoprecipitated from cytoplasmic and nuclear protein extracts from Vero cells, and in vitro kinase assays were performed (Fig. 3B). A phosphorylation of IE63 was observed with immunoprecipitated CKI and CKII either from the nucleus or cytoplasm of Vero cells, reinforcing our in vitro observations that both cellular CKI and CKII are capable of phosphorylating IE63.

We then decided to compare the relative phosphorylation...
rate of wild-type GST-IE63 in two different cell lines: Vero cells, which are non-neuronal and permissive cells, and ND7 cells, a neuronal cell line described previously (26) as non-permissive to HSV-1 infection. First, we investigated whether or not ND7 was also non-permissive to VZV infection. For this, Vero and ND7 cells were infected with cell-free virus for 24, 48, and 72 h. An immunofluorescence analysis was then carried out using an anti-IE63 monoclonal antibody. At 48 h post-infection, a few IE63-positive foci were observed in Vero cells, and their numbers largely increased 72 h post-infection (Fig. 4). At identical time points, neither IE63 expression nor cytopathic effect can be detected on ND7 cells, suggesting that this cell line is non-permissive to VZV infection.

In vitro kinase assays using total protein extracts from both
cell lines were then carried out in the presence or in the absence of DRB. PhosphorImaging and Coomassie Blue-stained SDS-PAGE gel densitometry analyses were used to determine the relative phosphorylation rate of the IE63 protein (Fig. 5). From several independent experiments, we observed that the level of phosphorylation was about 1.5-fold more important using extracts from Vero than ND7 cells. Furthermore, the level of phosphorylation was significantly reduced using 1 mM DRB, suggesting the involvement of CKI and/or CKII in both cell types (Fig. 5A). In vitro kinase assays using cellular protein extracts from Vero and ND7 cells were also carried out with the wild-type GST-IE63 and GST-IE63-10M proteins as substrates (Fig. 5B). We observed that the mutation of the 10 putative IE63 phosphorylation sites had an impact on the phosphorylation rate of the protein, but did not lead to its complete depletion. Again, this observation suggests that cellular kinases might use other phosphorylation sites on IE63 than the one targeted by our study. We also determined the casein kinase activity measured for the GST-63-10M protein was about 0.26 unit/µg total protein extract from Vero cells and 0.21 unit/µg total protein extract from ND7 cells, indicating that the mutation of the 10 potential phosphorylations have an important impact on the phosphorylation rate of IE63 but did not prevent it to be phosphorylated by cellular kinases. Results are also given for GST alone as negative control.

**IE63 Phosphorylation Influences Its Cellular Localization**—We decided to investigate the importance of IE63 phosphorylation on its localization. Plasmids encoding the wild-type and mutated proteins were transfected in both Vero and ND7 cells. Their cellular localization was observed by immunostaining analysis using either monoclonal or polyclonal antibodies directed against IE63. Quantitative analysis was carried out, and the cellular localization of the proteins in both cell lines was determined, based on at least three independent experiments (Table II). Previous reports (20) revealed that during VZV lytic infection, IE63 is mainly localized in the nucleus of infected cells. When transfected in both Vero and ND7 cells, a prevalent nuclear localization of the protein with a slight cytoplasmic localization was observed (Fig. 6A). Indeed, IE63 was present in the nucleus of more than 90% of transfected cells. A positive control for the cytoplasmic localization of IE63 was constructed. Based on a previous report (24), we removed the carboxyl-terminal region of IE63 (amino acids 210–278) necessary for the nuclear localization of the protein, in order to generate pcDNA63-ΔK. We also observed an almost complete cytoplasmic localization of this truncated protein when transfected either in Vero or in ND7 cells (Fig. 6B). About 82% of Vero cells expressing the protein exhibited a cytoplasmic staining, whereas in ND7 cells, almost all positive cells were stained in the cytoplasm (Table II). This localization of the protein could possibly be explained by the removal of a KRRR region coding for a putative nuclear localization signal (amino acids 260–264). It is also important to note the loss of two putative phosphorylation sites (Ser-224 and Thr-244) for
PKC/Cdc2 and CKI, respectively, in IE63/H9004. We decided then to remove solely the 260KRRR region coding for the putative nuclear localization signal (pcDNA63-H9004NLS). When transfected into Vero cells, we observed a major, but not exclusive, localization of this protein in the cytoplasm (Fig. 6C); 60% of Vero cells exhibited a cytoplasmic accumulation of IE63, whereas in the other 40%, the protein was evenly distributed between nucleus and cytoplasm (Table II). In ND7, up to 83% of transfected cells was positively stained in the cytoplasm. These results demonstrate that this 260KRRR region is a functional nuclear localization signal for the IE63 protein and is important for its nuclear localization in both cell lines. Meanwhile, as the IE63-H9004NLS protein was not exclusively confined to the cytoplasm of Vero cells, we might postulate that other surrounding residues of IE63 could participate to this process in that cell type.

No major impact on IE63 localization was observed when the first three putative phosphorylation sites for CKII (Ser-150, Ser-165, and Thr-171 into pcDNA63-1M, pcDNA63-2M, pcDNA63-3M, and pcDNA63-4M) were removed (data not shown). However, when Vero cells were transfected with pcDNA-5M, where the five putative phosphorylation sites for CKII (Ser-150, Ser-165, Thr-171, Ser-181, and Ser-186) were removed, a slight delocalization of the protein from the nucleus to the cytoplasm was observed in Vero cells (Fig. 6D). Indeed,
Directed against IE63 (staining analysis was carried out using a monoclonal antibody (9A12) used (BIE63-5M (21056) FITC. truncated IE63 proteins. Secondary antibodies used were coupled with phosphorylation sites were also included (pcDNA63-10M), we observed a striking accumulation of the protein at the nuclear envelope, just as if the protein had been excluded from the nucleus and was concentrating in the perinuclear space. In this case, more than 65% of Vero cells was stained predominantly in the nucleus, whereas about 23% of cells exhibited a uniform localization of IE63 between both cellular compartments, and 17% were marked mainly in the cytoplasm (Table II). In contrast, the IE63-5M protein was mainly localized in the nucleus of ND7 cells as the wild-type protein (Fig. 6D).

When mutations for the CKI and PKC/Cdc2 putative phosphorylation sites were also included (pcDNA63-10M), we observed an increasing delocalization of the IE63 protein from the nucleus to the cytoplasm of Vero cells (Fig. 6E). We also observed a striking accumulation of the protein at the nuclear envelope, just as if the protein had been excluded from the nucleus and was concentrating in the perinuclear space. In this case, more than 65% of the positive Vero cells exhibited a predominant cytoplasmic localization (Table II). Again, no major impact of these mutations was observed on the localization of the protein when transfected in ND7 cells (Fig. 6E). These results indicated an important role of the phosphorylation event in the cellular localization of the IE63 protein in Vero cells. In the neuronal cell line we tested, however, phosphorylation of these residues did not play an important role for the correct protein localization.

Phosphorylation Influences IE63 Regulating Properties—Regulatory properties of IE63 are still unclear at this time. It was shown previously (22) that this protein can either up-regulate the thymidine kinase gene or down-regulate the ORF62 gene, but these results were questioned by a later report suggesting a limited regulatory activity of IE63 on VZV gene expression (23). In this context, we decided to investigate in more detail the activity of IE63 and to observe the impact of phosphorylation events on gene regulation. The regulatory properties of the wild-type or mutated IE63 protein were assayed on the basal expression of the VZV DNA polymerase gene promoter (pPol). This promoter is an accurate tool for repression studies, as it exhibits a rather important constitutive activity. For this, transient transfections were carried out using a luciferase reporter gene under the control of the VZV pPol (pPol-luc). Vero and ND7 cells were transfected with 1 µg of this plasmid and with increasing concentrations of wild-type or mutated pcDNA63. Each independent condition tested was carried out using the same equimolar ratio of promoters. Results were expressed in percentage of stimulation with respect to the basal activity obtained with the pPol-luc alone (= 100%). First, the efficient expression of wild-type or mutated IE63 proteins was verified by Western blotting analysis (Fig. 7). In Vero or in ND7 cells, we observed a significant decrease of the basal luciferase activity when increasing concentrations of wild-type pcDNA63 were added (Fig. 8A). The observed repression was about 70% in both cell types at 6 µg of wild-type pcDNA63. In order to validate our reporter system, we tested the ability of IE63 to repress another VZV promoter. For this, we used the thymidine kinase promoter controlling the expression of the chloramphenicol acetyltransferase (CAT) reporter gene (Fig. 8B). We observed in this system that IE63 is also able, in both cell lines, to repress the basal activity of the thymidine kinase promoter to a similar level to what was observed with the VZV DNA polymerase promoter. All following experiments were then conducted using this pPol-luc reporter system. It is also important to note that a construct, where the wild-type IE63 gene had been cloned in the reverse orientation, was used as a negative control (pcDNA63inv).
With this plasmid transfected in identical conditions, as described above, no repression on the basal activity of the VZV DNA polymerase promoter was observed in both cell lines (Fig. 8C), demonstrating that the repressive activity of IE63 was due to the expression of a correctly expressed IE63.

When this experiment was performed using the IE63 protein mutated on the 10 potential phosphorylation sites (IE63-10M), no significant repression of the luciferase activity was observed in ND7 cells, whereas in Vero cells, this activity was greatly reduced (Fig. 8D). These results suggest the importance of the phosphorylation events for a complete and functional activity of IE63. This loss of activity seemed to be dependent on the phosphorylation mechanism and was not due to a change in the cellular localization in Vero cells, because experiments carried out with the pcDNA-63ΔNLS (Fig. 8E) revealed that IE63-ΔNLS, mainly localized in the cytoplasm, was still able to repress the basal activity of the promoter. The repression property observed with the IE63-ΔNLS protein was similar to that observed with the wild-type protein in both cell types, indicating that the 260KRRR region was not required for the activity of IE63 on this promoter. These results also suggest that IE63 is able to exert its activity by two independent ways, through a transcriptional or a post-transcriptional mechanism in the nucleus and/or a post-transcriptional mechanism in the cytoplasm. This phosphorylation-dependent regulation mechanism is not cell type-dependent because it was observed in both ND7 and Vero cells. Interestingly, we also observed that IE63, deleted from its carboxyl-terminal region (pcDNA-63 ΔK), was still able to act as a repressor on the luciferase reporter gene when transfected in Vero cells but not in ND7 cells (Fig. 8F).

These data suggest that, in ND7 cells, the repressive activity of IE63 is dependent on the carboxyl-terminal region (amino acids 210–278). This region contains a NLS and also two putative phosphorylation sites for PKC/Cdc2 or CKI. As experiments carried out with pcDNA63-ΔNLS showed that the NLS was not required for the activity of the protein, we might suspect that the presence of these two putative phosphorylation sites are important for the repressive activity of IE63 in ND7 cells but not crucial in Vero cells.

We also decided to evaluate the regulatory properties of wild-type or mutated IE63 when the expression of the pPol-luc promoter was stimulated by IE62, a VZV-encoded transcription factor. Indeed, it has been shown previously that IE62 was able to activate the VZV DNA polymerase promoter when transfected in cells (34). For this, Vero and ND7 cells were transfected with 1 µg of pPol-luc. Stimulation was achieved using 0.5 µg of pcDNA-IE62, and increasing concentrations of wild-type pcDNA63 or pcDNA63-10M were added. Results were presented in percentage of stimulation with respect to the stimulation obtained with 0.5 µg of pcDNA62. As expected, IE62 was able to stimulate the expression of the reporter gene up to 20-fold in Vero cells and about 10-fold in ND7 cells (data not shown). The difference in the level of pPol-luc stimulation between both cell lines could be explained by the fact that the level of basal expression of the VZV DNA polymerase promoter was higher in ND7 than in Vero cells. This stimulation was greatly reduced when increasing concentrations of wild-type IE63 were added, in both cell lines (Fig. 9A). Indeed, using 6 µg of wild-type pcDNA63, the stimulation of the promoter was about 30% that observed without IE63 in both cell types. Again, when the 10 putative phosphorylation sites of IE63 had been mutated, no repressive activity of the protein was observed in ND7 cells, whereas in Vero cells, this IE63-10M protein still exhibited some repressive properties (Fig. 9B).

**DISCUSSION**

The viral tegument is an amorphous structure located between the capsid and the external envelope of herpesviruses. Four different proteins, ORF10, IE4, IE62 and IE63, have been identified within the VZV tegument (35). They have all been described previously as regulatory proteins; ORF10, the homologue of HSV-1 VP16 protein, is able to transactivate the VZV IE62 promoter (36), whereas IE4 and IE62 are phosphoproteins known for their ability to stimulate the expression of all three classes of VZV genes (IE, E, and L) (4–8, 28). The activity of IE63 is not so well defined. This tegument protein possesses regulatory properties on the viral gene expression as shown previously (22), but these results were disputed (23).

The first part of this report was devoted to the analysis of the important phosphorylation sites of IE63. We showed that cellular kinases from both Vero and ND7 cells were able to phosphorylate this protein and that the phosphorylation rate of IE63 was higher in the permissive and non-neuronal cell line (Vero), compared with the neuronal but not permissive ND7 cells. Immunoprecipitation experiments and the use of a CKI and CKII inhibitor (DRB) in an *in vitro* kinase assay allowed us to conclude that those cellular kinases were implicated in IE63 phosphorylation. CKI and CKII are ubiquitous proteins involved in many cellular events; CKII is known to be implicated in various biological processes such as signal transduction, cell cycle, apoptosis, and cell transformation, and it can phosphorylate more than 160 proteins including many viral proteins (37). CKI was also described as a pleiotropic kinase with a large
number of substrates (38). Phosphorylation of IE63 in Mewo cells, or using recombinant CKII, was described previously (24), and potential phosphorylation sites were predicted in the carboxy-terminal region of the protein (between residues 142 and 278). A site-directed mutagenesis strategy allowed us to show that phosphorylation of IE63 was not restricted to the five serine or threonine residues targeted by CKII in this region (Ser-150, Ser-165, Thr-171, Ser-181, and Ser-186). Indeed, the IE63-5M protein, where all these potential CKII sites are mutated into alanine residues, may still be phosphorylated using recombinant CKII. These results suggest that CKII might also use target sites located elsewhere in the protein. Analysis of the amino acid sequence of the protein revealed the presence of two other putative phosphorylation sites for CKII in the amino-terminal (Thr-8) and in the central (Thr-124) parts of the protein. Using two other prediction programs (NetPhos 2.0 (39) and Scansite (40)) Ser-197 can also be identified as a residue with a high probability of being phosphorylated. According to the scansite program Ser-197 might be a potential target for CKII. The relevance and the implication of these sites in the phosphorylation of IE63 remain to be elucidated. We also observed a slightly higher CKI phosphorylation rate of IE63-5M in comparison with the wild-type protein. We suspect that phosphorylation of IE63 was not restricted to the five potential phosphorylation sites for CKII located in the carboxy-terminal region of IE63 led to a slight delocalization of the protein when transfected in Vero and in ND7 cells, confirming the observations of others in Mewo cells (24). The mutation of the five potential phosphorylation sites for CKII located in the carboxy-terminal region of IE63 led to a slight delocalization of the protein from the nucleus to the cytoplasm, impairing its transactivation properties (44). In this context, we investigate the impact of phosphorylation event on the cellular localization of IE63. The use of two different cell lines allowed us to compare the behavior of IE63 in a non-neuronal cell line permissive to VZV (Vero) and in neuronal ND7 cells, previously shown to be of low permissivity to HSV-1 infection (26). We demonstrated here that VZV does not replicate in this cell type.

Phosphorylation and dephosphorylation events are implicated in many cellular regulatory activities such as cell cycle, signal transduction, or gene expression (41–43). Many transcription factors are common targets for cellular kinases and are regulated by phosphorylation mechanisms (41, 42). Indeed, one of the strategies developed by cells to regulate the expression of cellular genes is the control of transcription factors localization and their shuttling through the nucleus. For example, phosphorylation of IE62 by the viral ORF66 kinase led to its delocalization from the nucleus to the cytoplasm, impairing its transactivation properties (44). Scansite analyses also revealed the presence of two other sites of high probability for being phosphorylated by CKI, Ser-15 and Ser-203. These residues might be responsible for the slight phosphorylation remaining in the IE63-10M mutated protein. Interestingly, we also noticed a lower CKII phosphorylation rate of the IE63-10M protein in comparison to what was observed with the IE63-5M. We postulate that the last mutations introduced in the IE63-10M protein (and especially the mutation of the residue 201) could have modified Ser-197 accessibility to CKII.

Kinase assays performed using cellular protein extracts and measure of the casein kinase activity revealed an important decrease (60–70% using Vero and ND7 protein extracts, respectively) of the phosphorylation rate of IE63-10M in comparison with the wild-type protein. This observation has been made regardless of the nature of the cell type, even if the phosphorylation rate of IE63 was more important using protein extracts from Vero than from ND7 cells. These results obtained with the neuronal and non-neuronal cellular models suggested that members of the casein kinase family are implicated in the phosphorylation of IE63.

Phosphorylation and dephosphorylation events are implicated in many cellular regulatory activities such as cell cycle, signal transduction, or gene expression (41–43). Many transcription factors are common targets for cellular kinases and are regulated by phosphorylation mechanisms (41, 42). Indeed, one of the strategies developed by cells to regulate the expression of cellular genes is the control of transcription factors localization and their shuttling through the nucleus. For example, phosphorylation of IE62 by the viral ORF66 kinase led to its delocalization from the nucleus to the cytoplasm, impairing its transactivation properties (44). In this context, we investigate the impact of phosphorylation event on the cellular localization of IE63. The use of two different cell lines allowed us to compare the behavior of IE63 in a non-neuronal cell line permissive to VZV (Vero) and in neuronal ND7 cells, previously shown to be of low permissivity to HSV-1 infection (26). We demonstrated here that VZV does not replicate in this cell type. The wild-type IE63 protein exhibits a major nuclear localization in Vero- and ND7-transfected cells, as observed previously (20) in infection studies. The removal of the four amino acids located between residues 260 and 264 (KRRR) led to a predominant cytoplasmic localization of the protein in both cell lines, suggesting that this short basic sequence acts as an effective, but not exclusive, nuclear localization signal for IE63. The removal of a large part of the carboxy-terminal region of the protein (IE63-ΔK) induced a cytoplasmic delocalization of the protein when transfected in Vero and in ND7 cells, confirming the observations of others in Mewo cells (24). The mutation of the five potential phosphorylation sites for CKII located in the carboxy-terminal region of IE63 led to a slight delocalization of the protein from the nucleus to the cytoplasm of Vero cells. Experiments carried out with mutants IE63-1M, IE63-2M, IE63-3M, and IE63-4M, where only some of the CKII phosphorylation sites were mutated, did not shed light on determining the CKII site responsible for this slight delocalization. Furthermore, the mutation of all CKI, CKII, and PKC/Cdc2 phosphorylation sites located in this area (IE63-10M) considerably alters the localization of IE63 in Vero cells, as more than 65% of them exhibited a major cytoplasmic staining. In this case, we also observed a striking localization of the protein at the nuclear membrane, suggesting that the absence of phosphorylation impaired its transport into the nucleus. Results obtained with several intermediate constructs, such as IE63-6M, IE63-7M, IE63-8M, and IE63-9M, did not allow us to identify a key site in the process (data not shown). Our observations suggest
that the correct import of IE63 into the nucleus requires a complete phosphorylation of the carboxyl-terminal region of the protein, rather than the phosphorylation of one or two particular sites. However, it should be pointed out that Ser-224 could also be considered as a potential target site for p34^cd2, a member of the cyclin-dependent serine/threonine kinase family involved in the G2/M transition of the cell cycle (45). It has been shown previously that, during HSV-1 infection, this cellular kinase is required for the expression of a subset of late viral proteins and that its own expression is induced by UL13 and ICP22, the latter being the HSV-1 homologue of IE63 (46).

Several reports (46–49) indicated that Cdc2 could modulate the cellular localization and the function of several transcription factors. In this context, it would be interesting to define the potential role that this kinase could play on the localization and/or activity of IE63. An interesting observation was also made when the cellular localization of IE63 mutated in some of its phosphorylation sites was investigated in ND7 cells. Indeed, in this neuronal cell line, no impact of the mutations of the phosphorylation sites was observed; the IE63-5M and IE63-10M proteins exhibited a nuclear localization like the wild-type protein, and after deletion of its NLS, the protein remains in the cytoplasm of transfected cells. These results indicate that in permissive cells (Vero), phosphorylation of the IE63 protein is important for its accurate localization, whereas in cells that do not support VZV infection (ND7), the phosphorylation rate of IE63 does not seem to be a critical factor for its subcellular localization. This suggests that, depending on the cell type, IE63 might use different transport mechanisms that could be more or less sensitive to its phosphorylation status. Numerous reports indicate that phosphorylation-dependent mechanisms may regulate the subcellular localization of proteins such as those containing a CCN motif, a short region containing phosphorylation sites for CKII and Cdc2 in the vicinity of a nuclear localization signal (50–54).

To understand the relevance of the phosphorylation-dependent localization of IE63, we developed an activity assay with the wild-type protein and then examined the behavior of the mutated proteins in this context. Because the trans-repressive properties of IE63 on IE promoters have been questioned (23), we investigated the activity of IE63 on the regulation of the gene encoding the DNA polymerase, a putative early protein (ORF28). Results indicated that the wild-type IE63 protein was able, in a dose-dependent way, to down-regulate the expression of the luciferase reporter gene driven by this promoter (pPol) in both cell lines tested. This repressive activity was clearly observed either in the basal activity of the pPol or after its stimulation by IE62. This down-regulating property might reflect an important role played by IE63 in the infectious cycle. An important feature of IE63 was observed when experiments were carried out with the 63ΔNLS protein. Indeed, despite its cytoplasmic localization, this protein was still capable of repressing the basal expression of the pPol. This property was established in neuronal and in non-neuronal cells with an efficiency similar to the wild-type protein. IE63 thus acts as a repressor either in the nucleus or in the cytoplasm of transfected cells, and this viral protein could exert its activity by two independent ways, through transcriptional and/or post-transcriptional mechanisms. Experiments carried out with the IE63-10M protein indicated that the phosphorylation status of IE63 is important for its activity. Indeed, in neuronal cells we observed a complete loss of the pPol repression when phosphorylation sites of the protein were mutated. These observations were made when pPol was stimulated by IE62 and on its basal activity. In Vero cells, the repression property of IE63 on the basal expression of the promoter was also slightly reduced. Hence, the phosphorylation status of IE63, rather than its cellular localization, is critical for the fulfillment of its repressive activity, and casein kinases are involved in the regulatory process. Several reports (37, 55, 56) indicate that members of the CK family possess regulatory properties and are involved in the control of cellular or viral gene expression.

Taken together, these results indicate that in the models studied, cellular CKI and CKII are important for the correct nuclear localization of IE63 and for its repressive properties in a cell type-dependent way. Furthermore, we showed that IE63 exerts its repressive properties in the nucleus as well as in the cytoplasm of transfected cell, suggesting its implication in transcriptional and/or post-transcriptional mechanism(s). In order to determine the biological relevance of our observations and to evaluate them in an infectious context, we intend to develop a VZV recombinant virus carrying mutations in the phosphorylation sites of IE63 genes. The replication of this recombinant virus will be tested in cultured cells, and its infectivity and its ability to establish latency in dorsal root ganglia will be addressed in our rat model. Recent studies (25) indicated that ORF47, one of the VZV-encoded kinase, is able to use IE63 as substrate in vitro. This Ser/Thr kinase has often been compared with CKII and is not essential for viral replication in cultured cells (57–60). Meanwhile, a study developed in a SCID-hu mice model indicated that ORF47 is required for viral growth in human T cells and skin (61). Although this suggested that in the differentiated cells studied endogenous CKII is unable to compensate the lack of ORF47, it will be necessary to clarify the ability of ORF47 to phosphorylate in vivo IE63 and to estimate the impact on its localization and activity before inferring a role for cellular kinases in the infection process.

Acknowledgment—We thank N. Renotte for technical assistance.

REFERENCES

1. Flisser, A., and Tapia-Couyer, R. (1999) Contrib. Microbiol. 3, 76–85
2. Lungu, O., and Annunziato, P. W. (1999) Contrib. Microbiol. 3, 61–75
3. Honess, R. W., and Roizman, B. (1974) J. Virol. 14, 8–19
4. Inchause, G., Nagpal, S., and Ostrove J. M. (1989) Virology 173, 700–709
5. Perera, I. P., Mosca, J. D., Sadeghi-Zadeh, M., Ruyechan, W. T., and Hay, J. (1992) Virology 191, 346–354
6. Kinezington, P., Hougland, J. K., Arvin, A. M., Ruyechan, W. T., and Hay, J. (1992) J. Virol. 66, 359–366
7. Perera, I. P., Mosca, J. D., Ruyechan, W. T., and Hay, J. (1992) J. Virol. 66, 5298–5304
8. Baudouin, L., Defechereux, P., Schoonbrodt, S., Merville, M. P., Rentier, B., and Piette, J. (1995) Nucleic Acids Res. 23, 1341–1349
9. Crowe, K. D., Ostrove, J. M., Dragovic, L. J., and Straus, S. E. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9773–9777
10. Meier, J. L., Holman, R. F., Crow, K. D., Smialek, J. E., and Straus, S. E. (1993) Virology 193, 193–200
11. Vafai, A., Wellish, M., and Gilden, D. H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 2767–2770
12. Cohrs, R. J., Strock, K., Barbour, M. B., Owens, G., Mahalingam, R., Devlin, M. E., Wellish, M., and Gilden, D. H. (1994) J. Virol. 68, 7900–7908
13. Cohrs, R. J., Barbour, M. B., Mahalingam, R., Wellish, M., and Gilden, D. H. (1995) J. Virol. 69, 2674–2678
14. Cohrs, R. J., Barbour, M. B., and Gilden, D. H. (1996) J. Virol. 70, 2789–2796
15. Kennedy, P., Grinfeld, E., and Gow, J. W. (1999) Virology 265, 451–454
16. Mahalingam, R., Wellish, M., Cohrs, R., Debrus, S., Piette, J., Rentier, B., and Gilden, D. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2122–2124
17. Lungu, O., Panagiotidis, C. A., Annunziato, P. W., Gershon, A. A., and Arvin, A. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7070–7075
18. Kennedy, P., Grinfeld, E., Bonziems, S., Sadzot-Delvaux, C., (2001) Virology 289, 218–223
19. Spengler, M., Niessen, N., Grose, C., Ruyechan, W. T., and Hay, J. (2001) Arch. Virol. 146 (suppl. 71–79
20. Debrus, S., Sadzot-Delvaux, C., Nikkelis, A. F., Piette, J., and Rentier, B. (1995) J. Virol. 69, 3240–3245
21. Sonnen, M. H., Zagha, E., Serrano, O. K., Ku, C. C., Zerboni, L., Baiker, A., Santos, R., Spengler, M., Lynch, J., Grose, C., Ruyechan, W., Hay, J., and Arvin, A. M. (2001) J. Virol. 75, 8224–8239
22. Jackers, P., Defechereux, P., Baudouin, L., Lambert, C., Massaer, M., Merville-Louis, M. P., Rentier, B., and Piette, J. (1992) J. Virol. 66, 3899–3903
23. Kost, R. G., Kupinsky, H., and Straus, S. E. (1995) Virology 209, 218–224
24. Stevenson, D., Xue, M., Hay, J., and Ruyechan, W. T. (1996) J. Virol. 70, 658–662
25. Kenyon, T. K., Lynch, J., Hay, J., Ruyechan, W., and Grose, C. (2001) J. Virol. 75, 8854–8868
26. Ng. T. I., and Grose, C. (1992) Virology 191, 9–18
VZV IE63 Phosphorylation

27. Wood, J. N., Bevan, S. J., Coote, P. R., Dunn, P. M., Harmar, A., Hogan, P., Latchman, D. S., Morrison, C., Roug, G., Theveniau, M., and Wheatley, S. (1990) Proc. R. Soc. Lond. 241, 187–194

28. Defechereux, P., Melen, L., Baudoux, L., Merville-Louis, M. P., Rentier, B., and Piette, J. (1993) J. Virol. 7, 4379–4385

29. Schoonbroodt, S., Piette, J., Merville, M.-P., Rentier, B., and Baudoux, L. (1993) J. Virol. 67, 4292–4300

30. Schoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J. R., Legrand-Poels, S., Korne, J.-P., and Piette, J. (1996) J. Med. Virol. 49, 264–273

31. Blom, N., Kreegipuu, A., and Brunak, S. (1998) Nucleic Acids Res. 26, 382–386

32. Lin, R., Beauparlant, P., Makris, C., Meloche, S., and Hiscott, J. (1996) Mol. Cell. Biol. 16, 1401–1409

33. Meggio, F., Shugar, D., Pinna, L. A. (1990) Eur. J. Biochem. 187, 89–94

34. Meier, J. L., Luo, X., Sawadogo, M., and Straus, S. E. (1994) Mol. Cell. Biol. 14, 6896–6906

35. Rahaus, M., Schunemann, S., and Wolff, M. H. (1999) Contrib. Microbiol. 3, 1–9

36. Moriuchi, H., Moriuchi, M., Straus, S. E., and Cohen, J. I. (1992) J. Virol. 67, 2739–2746

37. Guerra, B., and Iseinger, O.-G. (1999) Electrophoresis 20, 391–408

38. Gross, S. D., and Anderson, R. A. (1998) Cell. Signal. 10, 699–711

39. Blom, N., Gammeltoft, S., and Brunak, S. (1999) J. Mol. Biol. 294, 1351–1362

40. Yaffe, M. B., Leparc, G. G., Lai, J., Obata, T., Volinia, S., and Cantley, L. C. (2001) J. Mol. Biol. 317, 329–342

41. Kinchington, P. R., Fite, K., Seman, A., and Turse, S. E. (2001) J. Virol. 75, 9106–9113

42. King, R. W., Jackson, P. K., and Kirschner, M. W. (1994) Cell 79, 563–571

43. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

44. El-Hodiri, H. M., Che, S., Neutron-Gonzales, M., Kuan, J., and Etkin, L. D. (1997) J. Biol. Chem. 272, 20463–20470

45. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

46. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

47. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

48. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

49. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

50. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

51. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

52. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

53. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

54. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

55. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

56. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

57. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

58. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

59. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

60. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001

61. Advani, S. J., Weichselbaum, R. R., and Roizman, B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10996–11001